Cargando…

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Falguera, Daina, Iborra-Egea, Oriol, Gálvez-Montón, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698445/
https://www.ncbi.nlm.nih.gov/pubmed/34944652
http://dx.doi.org/10.3390/biomedicines9121836
_version_ 1784620281388597248
author Martínez-Falguera, Daina
Iborra-Egea, Oriol
Gálvez-Montón, Carolina
author_facet Martínez-Falguera, Daina
Iborra-Egea, Oriol
Gálvez-Montón, Carolina
author_sort Martínez-Falguera, Daina
collection PubMed
description Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application.
format Online
Article
Text
id pubmed-8698445
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86984452021-12-24 iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams Martínez-Falguera, Daina Iborra-Egea, Oriol Gálvez-Montón, Carolina Biomedicines Review Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application. MDPI 2021-12-05 /pmc/articles/PMC8698445/ /pubmed/34944652 http://dx.doi.org/10.3390/biomedicines9121836 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martínez-Falguera, Daina
Iborra-Egea, Oriol
Gálvez-Montón, Carolina
iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title_full iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title_fullStr iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title_full_unstemmed iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title_short iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
title_sort ipsc therapy for myocardial infarction in large animal models: land of hope and dreams
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698445/
https://www.ncbi.nlm.nih.gov/pubmed/34944652
http://dx.doi.org/10.3390/biomedicines9121836
work_keys_str_mv AT martinezfalgueradaina ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams
AT iborraegeaoriol ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams
AT galvezmontoncarolina ipsctherapyformyocardialinfarctioninlargeanimalmodelslandofhopeanddreams